Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes
Clinical trial NCT03551626 · COMPLETED
Trial details
- NCT number
- NCT03551626
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-08-29
- Primary completion
- 2020-10-05
- Enrollment
- 552
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.